Montelukast Sodium Tablet, Chewable
Product Images NDC 33342-111

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 33342-111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mont 4 mg 100s

Montelukast Sodium Chewable Tablets USP 4 mg packaging label showing product for pediatric patients 2-5 years, manufactured by Macleods Pharmaceuticals Limited. The label includes dosage strength, manufacturer details, barcode, storage instructions, and a warning that the unit dose package is not child resistant. The package contains 100 unit-dose chewable tablets.*

FDA Label Image

Mont 4 mg 30s

Montelukast Sodium 4 mg chewable tablets label from Macleods Pharmaceuticals Limited. The label states the product is for pediatric patients aged 2 to 5 years and includes storage instructions, dosage strength, quantity of 30 tablets, and manufacturer details. Contains warnings for phenylketonurics and specifics about tablet content and packaging.*

FDA Label Image

Mont 5 mg 100s

Montelukast Sodium Chewable Tablets USP 5 mg tablet packaging label for oral use. The label indicates the product contains 100 unit-dose tablets, for pediatric patients aged 6-14 years. It is manufactured by Macleods Pharmaceuticals Limited and labeled by Macleods Pharma USA, Inc. The packaging includes dosage instructions, storage conditions, and a barcode.*

FDA Label Image

Mont 5 mg 30

Montelukast Sodium 5 mg chewable tablets label from Macleods Pharmaceuticals Limited. The label indicates the tablets are for pediatric patients aged 6-14 years and are packaged in containers of 30 tablets. Storage instructions and manufacturing details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. in India are included. The label also provides the NDC number 33342-111-07.*

FDA Label Image

Mont Figure 1

A line graph showing change in height (cm) over weeks on treatment for Montelukast 5 mg, Beclomethasone 336 mcg, and placebo groups. The x-axis represents weeks on treatment, and the y-axis shows change in height. The graph compares growth outcomes in three groups over approximately 56 weeks.*

FDA Label Image

Mont Figure 2

A line graph showing mean percent change from baseline over weeks in treatment comparing placebo and Montelukast Sodium groups. The x-axis represents weeks in treatment (0 to 15), and the y-axis shows mean percent change from baseline (0 to 15). The graph includes data points connected by lines for placebo (square markers) and Montelukast Sodium (circle markers), including a washout period indicated at weeks 12 to 15.*

FDA Label Image

Mont Macleods

FDA Label Image

Mont Structure

Chemical structure of Montelukast sodium, showing its atomic arrangement including sodium salt and various aromatic and aliphatic groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.